The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Refludan lepirudin | Celgene Europe Ltd. | Thromboembolism; Thrombocytopenia | 🇪🇺 EU 1997-03-13 | Order → |
| Insuman insulin human | Sanofi-aventis Deutschland GmbH | Diabetes Mellitus | 🇪🇺 EU 1997-02-21 | Order → |
| LeukoScan sulesomab | Immunomedics GmbH | Osteomyelitis; Radionuclide Imaging | 🇪🇺 EU 1997-02-14 | Order → |
| Twinrix Paediatric hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed) | GlaxoSmithKline Biologicals S.A. | Immunization; Hepatitis B; Hepatitis A | 🇪🇺 EU 1997-02-10 | Order → |
| Hycamtin topotecan | Sandoz Pharmaceuticals d.d. | Ovarian Neoplasms; Uterine Cervical Neoplasms; Small Cell Lung Carcinoma | 🇪🇺 EU 1996-11-12 | Order → |
| Olansek olanzapine | Eli Lilly Co. Ltd. | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 1996-10-07 | Order → |
| CEA-Scan arcitumomab | Immunomedics GmbH | Radionuclide Imaging; Colorectal Neoplasms | 🇪🇺 EU 1996-10-04 | Order → |
| Crixivan indinavir | Merck Sharp & Dohme B.V. | HIV Infections | 🇪🇺 EU 1996-10-04 | Order → |
| Indimacis 125 igovomab | CIS bio international | Radionuclide Imaging; Ovarian Neoplasms | 🇪🇺 EU 1996-10-04 | Order → |
| Invirase saquinavir | Roche Registration GmbH | HIV Infections | 🇪🇺 EU 1996-10-03 | Order → |
| Zyprexa olanzapine | CHEPLAPHARM Registration GmbH | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 1996-09-27 | Order → |
| Twinrix Adult hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed) | GlaxoSmithKline Biologicals S.A. | Hepatitis B; Hepatitis A; Immunization | 🇪🇺 EU 1996-09-19 | Order → |
| Tecnemab K1 anti-melanoma mab fragments | Amersham Sorin S.r.l. | Radioimmunodetection | 🇪🇺 EU 1996-09-05 | Order → |
| Ecokinase reteplase | Roche Registration Ltd. | Myocardial Infarction | 🇪🇺 EU 1996-08-29 | Order → |
| Rapilysin reteplase | Actavis Group PTC ehf | Myocardial Infarction | 🇪🇺 EU 1996-08-29 | Order → |
| Norvir ritonavir | AbbVie Deutschland GmbH & Co. KG | HIV Infections | 🇪🇺 EU 1996-08-25 | Order → |
| Epivir lamivudine | ViiV Healthcare BV | HIV Infections | 🇪🇺 EU 1996-08-08 | Order → |
| Tritanrix HepB diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed) | GlaxoSmithKline Biologicals S.A. | Hepatitis B; Tetanus; Immunization; Whooping Cough; Diphtheria | 🇪🇺 EU 1996-07-19 | Order → |
| Bondronat ibandronic acid | Atnahs Pharma Netherlands B.V. | Hypercalcemia; Breast Neoplasms; Neoplasm Metastasis; Fractures, Bone | 🇪🇺 EU 1996-06-25 | Order → |
| Destara ibandronic acid | Roche Registration Ltd. | Hypercalcemia; Cancer | 🇪🇺 EU 1996-06-25 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.